A Randomised, Double-blinded, Multiple-dose, Dose-escalation Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Subjects With Overweight or Obesity
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2019
Price : $35 *
At a glance
- Drugs NNC0194 0499 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 21 Jun 2019 Status changed from active, no longer recruiting to completed.
- 09 May 2019 Planned End Date changed from 4 May 2019 to 12 Jun 2019.
- 09 May 2019 Planned primary completion date changed from 11 Apr 2019 to 12 Jun 2019.